Effects of angiotensin III on protein, DNA, and collagen synthesis of neonatal cardiomyocytes and cardiac fibroblasts in vitro.
This study compared angiotensin II (Ang II) and angiotensin III (Ang III) for their effects on rat neonatal cardiomyocytes and cardiac fibroblasts in vitro and discussed the possible role of Ang III in the pathogenesis of cardiac remodeling. To do so, protein synthesis, cardiac fibroblast proliferation, collagen synthesis, and secretion in response to treatment with Ang III and Ang II were investigated. Protein synthesis rate was assessed by (3)H-Leucine ((3)H-Leu) incorporation; the content of DNA was defined by (3)H-thymidine ((3)H-TdR) incorporation; and collagen synthesis and secretion were assessed by ( 3)H-proline ((3)H-Pro) incorporation. In neonatal cardiomyocytes, Ang III stimulated protein synthesis in a concentration-dependent manner, whereas in neonatal cardiac fibroblasts, DNA synthesis as well as collagen synthesis and secretion were increased in a concentration-dependent manner. Treatment with captopril, selective aminopeptidase A (APA) inhibitor (EC33), or selective aminopeptidase N inhibitor (PC18) had no effect on these outcomes. Treatment with losartan significantly decreased the effects of Ang III, except for cardiomyocyte protein synthesis. Compared with Ang II, Ang III could stimulate cardiomyocyte protein synthesis, cardiac fibroblast proliferation, and collagen synthesis and secretion. Furthermore, 10(-7) mol/L Ang II but not Ang III significantly increased APA activity in both cardiomyocytes and fibroblasts. All these results show the bioactive effects of Ang III on myocardial cells and suggest that Ang III could be an important independent factor besides Ang II in the regulation of cardiac function and may affect the pathogenesis of cardiac remodeling.
Wang
Hong Xia
HX
Department of Pathophysiology, Capital Medical University, Beijing, China.
Zhang
Qiu Fan
QF
Zeng
Xiang Jun
XJ
Wang
Wen
W
Tang
Chao Shu
CS
Zhang
Li Ke
LK
D000804:Angiotensin II / Q000378:metabolism / Q000494:pharmacology; D000805:Angiotensin III / Q000378:metabolism* / Q000494:pharmacology*; D000818:Animals; D000831:Animals, Newborn; D002216:Captopril / Q000378:metabolism / Q000494:pharmacology; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D003094:Collagen / Q000096:biosynthesis* / Q000378:metabolism; D004247:DNA / Q000096:biosynthesis* / Q000378:metabolism; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism*; D006321:Heart / Q000187:drug effects; D019808:Losartan / Q000378:metabolism / Q000494:pharmacology; D008297:Male; D008715:Methionine / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology; D009206:Myocardium / Q000166:cytology* / Q000378:metabolism; D032383:Myocytes, Cardiac / Q000187:drug effects / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D013451:Sulfonic Acids / Q000378:metabolism / Q000494:pharmacology
C472311:2-amino-4-methylsulfonyl butane thiol; C101968:EC 33; D013451:Sulfonic Acids; D000804:Angiotensin II; D000805:Angiotensin III; D003094:Collagen; D004247:DNA; D002216:Captopril; D008715:Methionine; D019808:Losartan